Quick navigation menu :

  1. Go to the content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the help menu
  5. Go to the modules
  6. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. US Web Sites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Sitemap |
  6. Help
  1. Font size

    Reduce font size Increase font size  
 

Press Releases

 
  1. Press Releases
  2. Press Statements
  3. SANOFI US PRESS KIT
  4. News Alerts
  5. Media Contacts
  6. Social Media
  7. Photos & Videos

Contact Us

Sanofi US
55 Corporate Drive
Bridgewater, NJ 08807



 

Our news releases are listed in chronological order and archived by year. To find news releases on a specific topic, utilize the search function.

Archives: Search / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

Category 

Dec 11, 2017
* First FDA-approved follow-on mealtime insulin
Dec 7, 2017
Phase 3 trials will evaluate isatuximab, an anti-CD38 antibody, in combination with other cancer treatments 
Dec 4, 2017
First head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo (insulin glargine 300 Units/mL) versus insulin degludec
Nov 30, 2017
Two large real-world analyses compared adults with type 2 diabetes who were switched to Toujeo (insulin glargine injection 300 Units/mL) to those switched to insulin degludec
 

2017 News Releases


Email information entered to email a page is only used to send the message and is not retained.

Corporate Information

Corporate Information